Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Azurrx Biopharma Inc (NQ: AZRX )

0.8199 USD +0.0199 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 703,606
Open 0.8070
Bid (Size) 0.8079 (1)
Ask (Size) 0.8199 (1)
Prev. Close 0.8000
Today's Range 0.7900 - 0.8250
52wk Range 0.6501 - 2.630
Shares Outstanding 74,439,377
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AzurRx BioPharma CEO Issues Letter to Shareholders
From GlobeNewswire News Releases
3 Reopening Penny Stocks to Watch in April 2021
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed

Performance

YTD
-8.90%
-8.90%
1 Month
-14.31%
-14.31%
3 Month
-46.76%
-46.76%
6 Month
+13.25%
+13.25%
1 Year
+7.88%
+7.88%

More News

Read More
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
From GlobeNewswire News Releases
Researchers Find Antioxidants That Can Help Prevent Cancerous HPV Infection in Women
From InvestorBrandNetwork
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
From GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update
From InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial
From InvestorBrandNetwork
Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction
From InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections
From InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial
From InvestorBrandNetwork
AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections
Tags Benzinga Market News AZRX
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.